智利簽署康希諾新冠疫苗採購協議 料第二季運抵
《新華社》報道,智利總統皮涅拉周二(30日)宣布,智利已簽署中國康希諾(06185.HK)新冠疫苗採購協議。皮涅拉指,智利公共衛生研究院有望在短時間內批准康希諾新冠疫苗的緊急使用許可,預期康希諾新冠疫苗將在今年第二季運抵智利,助智利迅速普及新冠疫苗接種。
康希諾新冠疫苗是中國軍事科學院軍事醫學研究院和康希諾公司聯合研發的腺病毒載體疫苗,目前正在智利等國進行三期臨床試驗。該疫苗已在中國、墨西哥、巴基斯坦和匈牙利等國獲得緊急使用許可。
智利於2月3日啟動全國新冠疫苗大規模接種。截至3月30日,智利全國已有658萬人接種了至少一劑疫苗。智利計劃今年上半年完成1,500萬人接種,約佔人口總數的80%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.